ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Harvard And Merck Form Research Pact

April 14, 2008 | APPEARED IN VOLUME 86, ISSUE 15

Harvard University's Office of Technology Development has signed a multiyear license and sponsored-research agreement with Merck & Co. focused on new osteoporosis therapies. Merck will fund research in the lab of immunology professor Laurie Glimcher. In return, it will get licenses to specific molecules that may result from the work. Glimcher studies the molecular pathways that lead to bone growth and looks for intervention points for enhancing bone formation or preventing osteoporosis in adults. Her lab has already identified several key mediators of bone growth that Merck hopes to use in the development of therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment